Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy

A case series report

David S. Ritchie, Richard L. Piekarz, Piers Blombery, Laszlo J. Karai, Stefania Pittaluga, Elaine S. Jaffe, Mark Raffeld, John Edward Janik, H. Miles Prince, Susan E. Bates

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. A phase II study exploring the efficacy of romidepsin, an histone deacetylase inhibitor, in patients with cutaneous or peripheral T-cell lymphomas was initiated at the National Cancer Institute. To date, over 120 patients with T-cell lymphoma have been treated on a multi-institutional phase II trial of romidepsin. Reactivation of latent DNA viruses including EBV, HBV, and VZV is well described as a consequence of the immune suppression associated with systemic chemotherapy. The incidence of viral reactivation in patients treated with histone deacetylase inhibitors is not yet known. We report the observation of EBV-associated illnesses in 2 patients and the reactivation of HBV in an additional patient treated with romidepsin. These cases may represent reactivation of DNA viruses due to histone deacetylase inhibitor induced immunosuppression, or direct promotion of viral replication via histone deacetylase inhibitor induced chromatin remodeling, or, alternatively, may be related to the underlying disease process. These observations suggest that vigilance for DNA virus reactivation is needed to quantify the risk in patients treated with histone deacetylase inhibitors.

Original languageEnglish (US)
Pages (from-to)1618-1622
Number of pages5
JournalHaematologica
Volume94
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

Histone Deacetylase Inhibitors
DNA Viruses
Human Herpesvirus 4
Therapeutics
Peripheral T-Cell Lymphoma
Chromatin Assembly and Disassembly
National Cancer Institute (U.S.)
T-Cell Lymphoma
Immunosuppression
Cell Death
Observation
Drug Therapy
Skin
Incidence
Growth
romidepsin

Keywords

  • DNA virus
  • Histone deacetylase inhibitor
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Ritchie, D. S., Piekarz, R. L., Blombery, P., Karai, L. J., Pittaluga, S., Jaffe, E. S., ... Bates, S. E. (2009). Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report. Haematologica, 94(11), 1618-1622. https://doi.org/10.3324/haematol.2009.008607

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy : A case series report. / Ritchie, David S.; Piekarz, Richard L.; Blombery, Piers; Karai, Laszlo J.; Pittaluga, Stefania; Jaffe, Elaine S.; Raffeld, Mark; Janik, John Edward; Miles Prince, H.; Bates, Susan E.

In: Haematologica, Vol. 94, No. 11, 01.11.2009, p. 1618-1622.

Research output: Contribution to journalArticle

Ritchie, DS, Piekarz, RL, Blombery, P, Karai, LJ, Pittaluga, S, Jaffe, ES, Raffeld, M, Janik, JE, Miles Prince, H & Bates, SE 2009, 'Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report', Haematologica, vol. 94, no. 11, pp. 1618-1622. https://doi.org/10.3324/haematol.2009.008607
Ritchie, David S. ; Piekarz, Richard L. ; Blombery, Piers ; Karai, Laszlo J. ; Pittaluga, Stefania ; Jaffe, Elaine S. ; Raffeld, Mark ; Janik, John Edward ; Miles Prince, H. ; Bates, Susan E. / Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy : A case series report. In: Haematologica. 2009 ; Vol. 94, No. 11. pp. 1618-1622.
@article{2120e8d744044a3686c653f1d9ef1056,
title = "Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report",
abstract = "Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. A phase II study exploring the efficacy of romidepsin, an histone deacetylase inhibitor, in patients with cutaneous or peripheral T-cell lymphomas was initiated at the National Cancer Institute. To date, over 120 patients with T-cell lymphoma have been treated on a multi-institutional phase II trial of romidepsin. Reactivation of latent DNA viruses including EBV, HBV, and VZV is well described as a consequence of the immune suppression associated with systemic chemotherapy. The incidence of viral reactivation in patients treated with histone deacetylase inhibitors is not yet known. We report the observation of EBV-associated illnesses in 2 patients and the reactivation of HBV in an additional patient treated with romidepsin. These cases may represent reactivation of DNA viruses due to histone deacetylase inhibitor induced immunosuppression, or direct promotion of viral replication via histone deacetylase inhibitor induced chromatin remodeling, or, alternatively, may be related to the underlying disease process. These observations suggest that vigilance for DNA virus reactivation is needed to quantify the risk in patients treated with histone deacetylase inhibitors.",
keywords = "DNA virus, Histone deacetylase inhibitor, Therapy",
author = "Ritchie, {David S.} and Piekarz, {Richard L.} and Piers Blombery and Karai, {Laszlo J.} and Stefania Pittaluga and Jaffe, {Elaine S.} and Mark Raffeld and Janik, {John Edward} and {Miles Prince}, H. and Bates, {Susan E.}",
year = "2009",
month = "11",
day = "1",
doi = "10.3324/haematol.2009.008607",
language = "English (US)",
volume = "94",
pages = "1618--1622",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "11",

}

TY - JOUR

T1 - Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy

T2 - A case series report

AU - Ritchie, David S.

AU - Piekarz, Richard L.

AU - Blombery, Piers

AU - Karai, Laszlo J.

AU - Pittaluga, Stefania

AU - Jaffe, Elaine S.

AU - Raffeld, Mark

AU - Janik, John Edward

AU - Miles Prince, H.

AU - Bates, Susan E.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. A phase II study exploring the efficacy of romidepsin, an histone deacetylase inhibitor, in patients with cutaneous or peripheral T-cell lymphomas was initiated at the National Cancer Institute. To date, over 120 patients with T-cell lymphoma have been treated on a multi-institutional phase II trial of romidepsin. Reactivation of latent DNA viruses including EBV, HBV, and VZV is well described as a consequence of the immune suppression associated with systemic chemotherapy. The incidence of viral reactivation in patients treated with histone deacetylase inhibitors is not yet known. We report the observation of EBV-associated illnesses in 2 patients and the reactivation of HBV in an additional patient treated with romidepsin. These cases may represent reactivation of DNA viruses due to histone deacetylase inhibitor induced immunosuppression, or direct promotion of viral replication via histone deacetylase inhibitor induced chromatin remodeling, or, alternatively, may be related to the underlying disease process. These observations suggest that vigilance for DNA virus reactivation is needed to quantify the risk in patients treated with histone deacetylase inhibitors.

AB - Histone deacetylase inhibitors are a class of anti-neoplastic agents that induce growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. A phase II study exploring the efficacy of romidepsin, an histone deacetylase inhibitor, in patients with cutaneous or peripheral T-cell lymphomas was initiated at the National Cancer Institute. To date, over 120 patients with T-cell lymphoma have been treated on a multi-institutional phase II trial of romidepsin. Reactivation of latent DNA viruses including EBV, HBV, and VZV is well described as a consequence of the immune suppression associated with systemic chemotherapy. The incidence of viral reactivation in patients treated with histone deacetylase inhibitors is not yet known. We report the observation of EBV-associated illnesses in 2 patients and the reactivation of HBV in an additional patient treated with romidepsin. These cases may represent reactivation of DNA viruses due to histone deacetylase inhibitor induced immunosuppression, or direct promotion of viral replication via histone deacetylase inhibitor induced chromatin remodeling, or, alternatively, may be related to the underlying disease process. These observations suggest that vigilance for DNA virus reactivation is needed to quantify the risk in patients treated with histone deacetylase inhibitors.

KW - DNA virus

KW - Histone deacetylase inhibitor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=70449365376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449365376&partnerID=8YFLogxK

U2 - 10.3324/haematol.2009.008607

DO - 10.3324/haematol.2009.008607

M3 - Article

VL - 94

SP - 1618

EP - 1622

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 11

ER -